Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of penpulimab plus lenalidomide, rituximab,
gemcitabine and oxaliplatin (R2-GemOx) in patients with relapsed/refractory diffuse large B
cell lymphoma (DLBCL). All patients will receive six cycles of penpulimab plus R2-GemOx.
Afterwards, 1) patients who achieve complete response (CR)/unconfirmed (CRu)/partial response
(PR) assessed by positron emission tomography/computedtomography (PET-CT) and are eligible
for autologous stem cell transplantation (ASCT) will undergo ASCT. 2) Patients who achieve
CR/CRu/PR assessed by PET-CT and are not eligible for ASCT will directly receive penpulimab
and lenalidomide as maintenance treatment, penpulimab for a maximum of 6 months, lenalidomide
monotherapy for 18 months. 3) Patients achieved stable disease (SD) or progression disease
(PD) assessed by PET-CT will withdraw from this study and receive proper treatment based on
investigator's decision.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University